GRTS Gritstone bio, Inc. revenue, earnings and financials
For the quarter ended June 30, 2024, Gritstone bio, Inc. reported revenue of $921K (down 52.9% from a year earlier), net income of −$23.4M and diluted EPS of −$0.16; over the last four quarters revenue was $14.6M and net income −$133M; for the fiscal year ended December 2023 revenue was $16.3M, down 18.1% on the year before.
GRTS annual revenue and earnings
- Fiscal year ended Dec 2023: revenue $16.3M, gross profit n/a, operating income −$140M, net income −$138M (margin -847.3%), EPS −$1.20
- Fiscal year ended Dec 2022: revenue $19.9M, gross profit n/a, operating income −$120M, net income −$120M (margin -600.1%), EPS −$1.32
- Fiscal year ended Dec 2021: revenue $48.2M, gross profit n/a, operating income −$75.2M, net income −$75.1M (margin -155.7%), EPS −$0.95
GRTS quarterly revenue and earnings
- Quarter ended Jun 30, 2024: revenue $921K (down 52.9% year over year), net income −$23.4M, EPS −$0.16
- Quarter ended Mar 31, 2024: revenue $1.74M (down 28.7% year over year), net income −$40.4M, EPS −$0.34
- Quarter ended Dec 31, 2023 (from the annual report): revenue $10.4M (up 143.6% year over year), net income −$30.8M, EPS −$0.26
- Quarter ended Sep 30, 2023: revenue $1.57M (down 48.2% year over year), net income −$38.4M, EPS −$0.33
- Quarter ended Jun 30, 2023: revenue $1.96M (down 64.3% year over year), net income −$35.3M, EPS −$0.31
- Quarter ended Mar 31, 2023: revenue $2.44M (down 66.0% year over year), net income −$34.0M, EPS −$0.30
- Quarter ended Dec 31, 2022 (from the annual report): revenue $4.26M (up 39.1% year over year), net income −$31.3M, EPS −$0.29
- Quarter ended Sep 30, 2022: revenue $3.02M (up 15.6% year over year), net income −$30.0M, EPS −$0.35
- Quarter ended Jun 30, 2022: revenue $5.47M (up 92.4% year over year), net income −$29.5M, EPS −$0.34
- Quarter ended Mar 31, 2022: revenue $7.19M (down 81.9% year over year), net income −$28.9M, EPS −$0.34
- Quarter ended Dec 31, 2021 (from the annual report): revenue $3.06M, net income −$29.8M, EPS −$0.36
- Quarter ended Sep 30, 2021: revenue $2.61M, net income −$28.1M, EPS −$0.36
- Quarter ended Jun 30, 2021: revenue $2.84M, net income −$25.1M, EPS −$0.33
- Quarter ended Mar 31, 2021: revenue $39.7M, net income $7.92M, EPS $0.10
GRTS cash flow, buybacks and dividends
- Fiscal year ended Dec 2023: operating cash flow −$122M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$116M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$50.7M, share buybacks n/a
GRTS balance sheet
- Jun 30, 2024: cash $50.9M, total assets $143M, total liabilities $120M, shareholders' equity $22.2M, long-term debt $40.5M
- Mar 31, 2024: cash $42.4M, total assets $137M, total liabilities $123M, shareholders' equity $14.0M, long-term debt $40.3M
- Dec 31, 2023: cash $63.0M, total assets $178M, total liabilities $126M, shareholders' equity $51.9M, long-term debt $40.1M
- Sep 30, 2023: cash $29.5M, total assets $187M, total liabilities $113M, shareholders' equity $74.0M, long-term debt $29.9M
- Jun 30, 2023: cash $41.4M, total assets $223M, total liabilities $113M, shareholders' equity $110M, long-term debt $29.7M
- Mar 31, 2023: cash $47.1M, total assets $210M, total liabilities $69.1M, shareholders' equity $141M, long-term debt $29.6M
- Dec 31, 2022: cash $55.5M, total assets $241M, total liabilities $70.0M, shareholders' equity $171M, long-term debt $19.3M
- Sep 30, 2022: cash $64.9M, total assets $205M, total liabilities $68.4M, shareholders' equity $137M, long-term debt $19.3M
What is GRTS's revenue?
Gritstone bio, Inc. reported $14.6M of revenue over its last four quarters, through June 30, 2024.
Is GRTS profitable?
No. Gritstone bio, Inc. lost $133M over the last four quarters.
What is GRTS's EPS?
Diluted earnings per share over the last four quarters were −$1.09; −$0.16 in the latest quarter.